Centocor, Inc., a Johnson & Johnson company, has expanded its earlier license and option agreement to use Vical‘s Incorporated naked DNA technology to develop and commercialize certain DNA vaccines for the potential treatment of some types of cancer. Vical will receive an undisclosed upfront payment and could receive additional milestone payments in the future. The Read more about Centocor Expands Cancer Vaccine Agreement[…]